Effects of simvastatin in abdominal sepsis in rats

Acta Cirurgica Brasileira

Volumn 21, Issue SUPPL. 4, 2006, Pages 8-12

  Neto, José Luiz De Souza ^a   Araújo Filho, Irami ^a   Do Rego, Amália Cínthia Meneses ^b   Dominici, Víctor Almeida ^b   Azevedo, Ítalo Medeiros ^b   Egito, Eryvaldo Sócrates Tabosa ^b   Brandão Neto, José ^b   Medeiros, Aldo Cunha ^b,c  

^a Program in Health Sciences UFRN   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^c NONE   (Brazil)

Author keywords

Abdominal sepsis; Cytokine; Inflammation; Leukocyte; Statin; Wistar rat

Indexed keywords

ANTILIPEMIC AGENT; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CECUM LIGATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EXPERIMENTAL MODEL; LEUKOCYTE COUNT; LIGATION; NEUTROPHIL COUNT; NONHUMAN; PUNCTURE; RAT; SEPSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CECUM; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUKOCYTES; LYMPHOCYTES; NEUTROPHILS; RANDOM ALLOCATION; RATS; RATS, WISTAR; SEPSIS; SIMVASTATIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846930580     PISSN: 01028650     EISSN: 16782674     Source Type: Journal    
DOI: 10.1590/S0102-86502006001000003     Document Type: Article

References (40)

1. Kumana CR, Cheung BM, Lauder IJ. Simvastatin reduced mortality and vascular events in high-risk patients. ACP J Club. 2003; 138:2-3.
2. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350:1495-504.
3. Arnaud C, Mach F. Pleiotropic effects of statins in atherosclerosis: role on endothelial function, inflammation and immunomodulation. Arch Mal Coeur Vaiss. 2005; 98:661-6.
4. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003; 348:138-50.
5. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med. 2003; 9:517-24.
6. Bone RC, Fisher CJ Jr, Clemmer TP. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987; 317:653-8.
7. Annane D. Corticosteroids for septic shock. Crit Care Med. 2001;29:S117-S20.
8. Bernard GR, Vincent JL, Laterre PF. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001; 344:699-709.
9. Fisher CJ, Agosti JM, Opal SM. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med. 1996; 334:1697-702].
10. Fisher CJ Jr, Slotman GJ, Opal SM. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. The IL-1RA Sepsis Syndrome Study group. Crit Care Med. 1994; 22:12-21.
11. Ziegler EJ, Fisher CJ Jr, Sprung CL. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med. 1991; 324:429-36.
12. Bernard GR, Wheeler AP, Russel JA, Schein R, Steinberg JP, Fulkerson WJ, Wright PE, Christman BW, Dupont WD, Higgins SB, Swindell BB. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med. 1997; 336:912-18.
13. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6:1399-402.
14. Pruefer D, Makowski J, Schnell M, Buerke U, Dahm M, Oelert H, Sibekius U, Grandel U, Grimminger F, Seeger W, Meyer J, Darius H, Buerke M. Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha toxin. Circulation. 2002; 106:2104-10
15. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998;273:24266-71.
16. Endo A, Kuroda M. Citrinin, an inhibitor of cholesterol synthesis. J Antibiot. 1976; 29: 841-3.
17. Brown AG, Smale TC, King TJ, Hasenkamp R, Thompson RH. Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum. J Chem Soc. 1976; 1:1165-70.
18. Endo A.The discovery and development of HMG-CoA reductase inhibitors. J of Lipid Res. 1992; 33: 1569-1582.
19. Goldberg AC. Clinical implications of statin event trials. Curr Atheroscler Rep. 2002;4:337-42.
20. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. J Am Med Assoc. 1998; 279:1643-50.
21. Eisenberg DA. Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials. Am J Med. 1998; 104(2A):2S-5S.
22. Mach F. Toward a role for statins in immunomodulation. Mol Interv. 2002; 2:478-80.
23. Veillard N, Mach F. Statins: The new aspirin? Cell Mol Life Sci. 2001; 11: 1771-87.
24. Palinski W. Immunomodulation: A new role for statins? Nat Med. 2000; 12:1311-2.
25. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998; 97: 1129-35.
26. Garrido AG, Figueiredo LFP, Silva MR. Experimental models of sepsis and septic shock: an overview. Acta Cir Bras. 2004; 19: 82-8.
27. Rodrigues FHOC, Carneiro BGMC, Rocha RF, Petroianu A. Inibição da formação de abscesso abdominal em rato - mortalidade por sepse. Exp Gastroenterol. 2005; 42:50-4.
28. D'acampora AJ, Bernhardt JA, Serafim JDM, Farias DC, Tramonte R. Efeitos da castração pós-natal sobre o tecido pulmonar após sepse experimental de origem abdominal em ratos. Acta Cir Bras. 2004; 19:115-9.
29. Villa P, Sartor G, Angelini M, Sironi M, Conni M, Gnocchi P, Isetta AM, Grau G, Buurman W, van Tits LJ. Pattern of cytokines and pharmacomodulation in sepsis induced by cecal ligation and puncture compared with that induced by endotoxin. Clin Diagn Lab Immunol. 1995; 2:549-53.
30. Koo DJ, Zhou M, Jackman D, Cioffi WG, Bland KI, Chaudry IH, Wang P. Is gut the major source of proinflammatory cytokine release during polymicrobial sepsis? Biochim Biophys Acta. 1999; 1454:289-95.
31. Merx MW, Liehn AE, Janssens U, Lütticken, R, Schrader J, Hanrath P, Weber C. HMG-CoA Reductase Inhibitor Simvastatin Profoundly Improves Survival in a Murine Model of Sepsis. Circulation. 2004; 109:2560-5.
32. Merx MW, Liehn EA, Graf J, van de Sandt A, Schaltenbrand M, Schrader J, Hanrath P, Weber C. Statin treatment after onset of sepsis in a murine model improves survival. Circulation. 2005; 112:117-24.
33. Alkharfy KM, Kellum JA, Frye RF, Matzke GR. Effect of Ceftazidime on Systemic Cytokine Concentrations in Rats. Antimicr Agent Chemother. 2000;44: 3217-9.
34. Chandraa A, Enkhbaatarb P, Nakanob Y, Traberb LD, Traberb DL. Sepsis: Emerging role of nitric oxide nd Selectins. Clinics. 2006; 61:71-6.
35. Almog Y. Statins, Inflammation, and Sepsis. Chest. 2003; 124:740-3.
36. Salles MJC, Sprovieri SRS, Bedrikow R, Pereira AC, Cardenuto SL, Azevedo PRC, Silva TM, Golin V. Síndrome da resposta inflamatória sistêmica/sepse - revisão e estudo da terminologia e fisiopatologia. Rev Ass Med Bras. 1999; 45:86-92.
37. Warnholtz A, Genth-Zotz S, Münzel T. Should Treatment of Sepsis Include Statins.? Circulation. 2005; 111:1735-7.
38. Pleiner J, Schaller G, Mittermaye Fr; Zorn S, Marsik C, Polterauer S, Kapiotis S, Wolzt M. Simvastatin Prevents Vascular Hyporeactivity During Inflammation. Circulation. 2004; 110:3349-54.
39. Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, Friger M, Zeller L, Danon A. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation. 2004; 110:880-5.
40. Liappis AP, Kan VL, Rochester CG, Simon GL. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis.2001; 33:1352-7.